Cite
HARVARD Citation
Kerr, R. et al. (n.d.). Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. Lancet oncology. 17 (11), pp. 1543-1557. [Online].